Immunothérapie et évaluation de la réponse tumorale : la difficulté de la pseudoprogression

详细信息    查看全文

• 作者：E. Loir ; A. Jouinot
• 关键词：Mots clésPseudoprogression ; Immunothérapie ; irRC
• 刊名：Oncologie
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：18
• 期：9-10
• 页码：523-526
• 全文大小：319 KB
• 刊物主题：Oncology;
• 出版者：Springer Paris
• ISSN：1765-2839
• 卷排序：18

文摘

The monitoring of patients treated with immunotherapy has highlighted a phenomenon of prolonged secondary response despite initial progression, known as pseudoprogression. Therefore, the evaluation of tumour response cannot be performed using just RECIST 1.1 criteria, which are routinely used within oncology. irRC (immune-related Response Criteria) criteria have been developed to assist; however, they currently have limitations: a two-dimensional evaluation of the tumour size, barely used in oncology today, and an absence of validation on a large cohort, and this based on various types of immunotherapy and in different indications. The strongest consensus of opinion is to continue with treatment despite RECIST progression only in cases where there is a clinical benefit to the patient.